These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 12820359

  • 1. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 3. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 4. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases.
    Oremek GM, Müller R, Sapoutzis N, Wigand R.
    Anticancer Res; 2003; 23(2A):1131-4. PubMed ID: 12820360
    [Abstract] [Full Text] [Related]

  • 5. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 6. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 7. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 8. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 9. Tumor M2-PK levels in haematological malignancies.
    Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Anticancer Res; 2003 Apr; 23(2A):1135-8. PubMed ID: 12820361
    [Abstract] [Full Text] [Related]

  • 10. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000 Apr; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 11. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E.
    Cancer Detect Prev; 2000 Apr; 24(6):531-5. PubMed ID: 11198266
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K.
    Anticancer Res; 2000 Apr; 20(6D):5077-82. PubMed ID: 11326672
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 16. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2003 Jun; 23(2A):991-7. PubMed ID: 12820337
    [Abstract] [Full Text] [Related]

  • 17. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU.
    Anticancer Res; 2003 Jun; 23(2A):851-3. PubMed ID: 12820312
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
    Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, Corinaldesi R.
    Anticancer Res; 2003 Jun; 23(3C):2969-72. PubMed ID: 12926146
    [Abstract] [Full Text] [Related]

  • 19. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.